Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Indolent Non-Hodgkin Lymphoma”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Early research (Phase 1)Active Not RecruitingNCT06824701
What this trial is testing

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah 24
Testing effectiveness (Phase 2)Ended earlyNCT01944943
What this trial is testing

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System Lymphoma+1 more
The Lymphoma Academic Research Organisation 31
Testing effectiveness (Phase 2)Looking for participantsNCT07365306
What this trial is testing

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Mediastinal Large B-Cell Lymphoma+5 more
City of Hope Medical Center
Not applicableEnded earlyNCT00005786
What this trial is testing

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaProlymphocytic Leukemia+8 more
National Cancer Institute (NCI) 25
Early research (Phase 1)Study completedNCT02417285
What this trial is testing

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Celgene 75
Large-scale testing (Phase 3)Study completedNCT01321541
What this trial is testing

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Who this might be right for
Diffuse Large B-cell Lymphomade Novo DLBCLDLBCL Transformed From Indolent Lymphoma+1 more
CTI BioPharma 312
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Testing effectiveness (Phase 2)Looking for participantsNCT06386315
What this trial is testing

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent Indolent B-Cell Non-Hodgkin LymphomaRefractory Indolent B-Cell Non-Hodgkin Lymphoma+2 more
Mayo Clinic 112
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)WithdrawnNCT01238146
What this trial is testing

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+4 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT02747732
What this trial is testing

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal (Thymic) Large B-cell LymphomaTransformed Indolent Lymphoma+2 more
Meirav Kedmi MD 72
Early research (Phase 1)Study completedNCT00082784
What this trial is testing

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Who this might be right for
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell Lymphoma+10 more
National Cancer Institute (NCI) 93
Early research (Phase 1)WithdrawnNCT04836832
What this trial is testing

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone Lymphoma+6 more
Narendranath Epperla
Testing effectiveness (Phase 2)Study completedNCT00005579
What this trial is testing

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
University of Vermont
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Next Page
43